Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2021 Mar 6;9(7):2645–2655.e14. doi: 10.1016/j.jaip.2021.02.041

Chronic Respiratory Diseases and the Outcomes of COVID-19: A Nationwide Retrospective Cohort Study of 39,420 Cases

Wei-jie Guan a,, Wen-hua Liang a,b,, Ying Shi c,, Lan-xia Gan c,, Hai-bo Wang d,, Jian-xing He a,b,, Nan-shan Zhong a
PMCID: PMC7935669  PMID: 33684635

Abstract

Background

Chronic respiratory diseases (CRD) are common among patients with coronavirus disease 2019 (COVID-19).

Objectives

We sought to determine the association between CRD (including disease overlap) and the clinical outcomes of COVID-19.

Methods

Data of diagnoses, comorbidities, medications, laboratory results, and clinical outcomes were extracted from the national COVID-19 reporting system. CRD was diagnosed based on International Classification of Diseases-10 codes. The primary endpoint was the composite outcome of needing invasive ventilation, admission to intensive care unit, or death within 30 days after hospitalization. The secondary endpoint was death within 30 days after hospitalization.

Results

We included 39,420 laboratory-confirmed patients from the electronic medical records as of May 6, 2020. Any CRD and CRD overlap was present in 2.8% and 0.2% of patients, respectively. Chronic obstructive pulmonary disease (COPD) was most common (56.6%), followed by bronchiectasis (27.9%) and asthma (21.7%). COPD-bronchiectasis overlap was the most common combination (50.7%), followed by COPD-asthma (36.2%) and asthma-bronchiectasis overlap (15.9%). After adjustment for age, sex, and other systemic comorbidities, patients with COPD (odds ratio [OR]: 1.71, 95% confidence interval [CI]: 1.44-2.03) and asthma (OR: 1.45, 95% CI: 1.05-1.98), but not bronchiectasis, were more likely to reach to the composite endpoint compared with those without at day 30 after hospitalization. Patients with CRD were not associated with a greater likelihood of dying from COVID-19 compared with those without. Patients with CRD overlap did not have a greater risk of reaching the composite endpoint compared with those without.

Conclusion

CRD was associated with the risk of reaching the composite endpoint, but not death, of COVID-19.

Key words: Asthma, Chronic obstructive pulmonary disease, Bronchiectasis, Death, Composite endpoint

Abbreviations used: CI, Confidence interval; COPD, Chronic obstructive pulmonary disease; COVID-19, Coronavirus disease 2019; CRD, Chronic respiratory disease; EMR, Electronic medical records; OR, Odds ratio


What is already known on this topic? The impact of chronic respiratory diseases (CRD) on severe coronavirus disease 2019 (COVID-19) and the risk of death remains controversial.

What does this article add to our knowledge? Patients with chronic obstructive pulmonary disease (COPD) and asthma were more likely to reach the composite endpoint (needing invasive ventilation, admission to intensive care unit, or death within 30 days after hospitalization) compared with those without, after adjusting for age, sex, and other systemic comorbidities. However, patients with CRD did not have an increased risk of death compared with those without.

How does this study impact current management guidelines? Both COPD and asthma are important risk factors of poor clinical outcomes but not death in patients with COVID-19.

Coronavirus disease 2019 (COVID-19) is a severe acute respiratory disease that occurs globally, resulting in more than 53,000,000 laboratory-confirmed cases and 1,300,000 deaths as of early November, according to the World Health Organization.1 COVID-19 is a highly heterogeneous disease that ranges from mild diseases that could be asymptomatic to a critical illness that might rapidly progress to death.2 , 3 Early identification of the risk factors that predispose to poor clinical outcomes of COVID-19 may help early triage of patients and improve the prognosis.4

An important predictor of the risk of progression to severe or critical illness has been the presence, category, and number of comorbidities.5, 6, 7, 8 Comorbidities were reportedly common among patients with COVID-19 and correlated significantly with the clinical outcomes.5, 6, 7, 8 According to a modeling study, approximately 20% of the world's population could have an increased risk of developing severe COVID-19, with the presence of at least 1 comorbidity being an important contributing factor.9 Although the impact of major cardiovascular and metabolic diseases such as hypertension and diabetes on the clinical outcomes of COVID-19 has been mostly consistent, the findings regarding respiratory comorbidities remain less clear. A recent study documented a contrasting impact of asthma and chronic obstructive pulmonary disease (COPD) on the risk of death in 961 hospitalized patients with COVID-19.6 A meta-analysis also documented a substantial variability of the prevalence of asthma among patients with COVID-19 and a lower risk of death in patients with asthma compared with those without.10 Furthermore, the studies reporting chronic respiratory diseases (CRD), including asthma, COPD, and bronchiectasis, in patients with COVID-19 have been limited by the small sample sizes and single disease entity.5 , 11 , 12

We hypothesized that CRD would confer an adverse impact on the clinical outcomes of COVID-19. On the basis of a nationwide database, we sought to explore the association between CRD and the clinical outcomes of COVID-19.

Study Design and Methods

Study patients

In this retrospective cohort study, data were derived from the national COVID-19 reporting system, a platform of in-patient electronic medical records (EMR) authorized by National Health Commission. Since the initial outbreak, submission of the EMR from individual hospitals designated for admitting patients with COVID-19 was requested by the National Health Commission. We extracted the data of the clinical diagnoses, comorbidities, medications, laboratory results, and clinical outcomes from the EMR. As of May 6, 2020 (the data cutoff date for our study), the database consisted of 42,218 in-patient EMR records, covering 558 designated hospitals. To be eligible for data inclusion in our analysis, all hospitalized patients had to have a diagnosis of laboratory-confirmed COVID-19. All patients had established CRD before admission. We excluded patients without any information on the comorbidities and the clinical outcomes (dead or alive, receipt of mechanical ventilation, and admission to intensive care unit). This study was approved by the ethics committee of the First Affiliated Hospital of Guangzhou Medical University (Institutional Review Board: 202092). Written informed consent form was waived because of the anonymized data extraction of the EMR.

Study design and data extraction

This was a retrospective cohort study that was conducted between December 2019 and May 6, 2020. All hospitalized patients were prospectively followed up until 30 days after hospitalization. Within the EMR, each standardized in-patient discharge summary consisted of the following items: (1) demographics (ie, gender, date of birth, occupation, and geographic location); (2) the primary and secondary discharge description, coded based on the International Classification of Diseases-10; (3) the main treatment description and discharge records; (4) in-hospital outcomes (ie, death and length of hospital stay); and (5) discharge or death summary (ie, medications and discharge outcomes).

In this study, CRD consisted of asthma, COPD, and bronchiectasis. The physician diagnosis of COPD, asthma, and bronchiectasis (radiological with or without clinical bronchiectasis) at hospital admission or discharge from hospital was extracted with the computer software based on the International Classification of Disease-10 codes from the EMR. All diagnoses of CRD were made based on either the past history that was documented in the patient's clinical charts, or the clinical manifestations consistent with the global guidelines (such as the Global Initiatives for Obstructive Lung Disease and Global Initiatives for Asthma).

At the request of the National Health Commission, all medical records were stored centrally in the Tianhe-2 supercomputer, the data processing center in Guangzhou. A team of experienced computing scientists and bioinformatics data managers formulated the clinical data and electronically extracted the data with a customized operating system from the clinical charts and the portable document format files. Data were exported into a computerized database for further cross-check.

Study definitions

Chronic respiratory disease overlap denoted at least 2 coexisting CRD. At hospital admission, patients were stratified into having nonsevere (common type), or severe (respiratory rate ≥30/min, dyspnea, oxygenation index <300) or critical illness of COVID-19 (needing intensive care), based on the criteria established by The Diagnosis and Treatment Protocol for COVID-19 (Trial Version 5).13 The primary endpoint, the composite outcome, was defined as needing invasive ventilation, admission to the intensive care unit, or death within 30 days after hospitalization.5 The secondary endpoint was death within 30 days after hospitalization.

Statistical analysis

In this study, we took a stepwise approach for examining the completeness of the core data sets. Specifically, we initially verified the completeness of data pertaining to the age and sex, followed by the discharge status, and the date of hospital admission. Continuous variables were presented as the medians and interquartile ranges or ranges as appropriate, and the categorical variables were displayed as the counts and percentages. Patients were categorized according to the presence or absence of any CRD. The risks of death or reaching to composite outcomes were analyzed using the Cox proportional hazards model, with the adjustment for the age, female sex, and the presence of any other systemic comorbidity. The odds ratio (OR) and 95% confidence interval (95% CI) were calculated for the comparison of the difference in the survival risk. We have further adjusted for these potential confounding factors (including age, sex, and other systemic comorbidities) with the multivariate model to determine how they correlated with the study endpoints. No imputation was applied for missing data. Analyses were conducted with R software version 3.6.0 (packages: survival, survminer, dplyr, data.table). A P value of .05 or lower was deemed statistically significant for the regression analysis.

Results

Data inclusion

We included 39,420 laboratory-confirmed patients of 42,218 (93.4%) patients after excluding patients with missing data (age or sex [n = 456], discharge records [n = 1647], and admission date [n = 695]) (Figure 1 ). A total of 2053 (5.21%) deaths were recorded. Patients who were included in our analysis had comparable demographic characteristics compared with those who were not (Table I ).

Figure 1.

Figure 1

Study flowchart. COPD, Chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; EMR, electronic medical records.

Table I.

Characteristics of the patients who were included in the final analysis and those excluded

Variables Included cases (n = 39,420) Excluded cases (n = 2798) P value
Mean age (y) 55.7 55.4 .434
Females, n (%) 19,765 (50.1) 1415 (50.6) .659
Mortality, n (%) 2053 (5.2) 139 (5.0) .580
Reaching the composite endpoint, n (%) 5559 (14.1) 225 (8.0) <.001

Events that took place within 30 days after hospitalization.

Baseline characteristics

Any CRD and CRD overlap was present in 2.8% (n = 1123) and 0.2% (n = 69) of all patients, respectively. COPD was the most common CRD (n = 636, 56.6%), followed by bronchiectasis (n = 313, 27.9%) and asthma (n = 244, 21.7%). For CRD overlap, COPD-bronchiectasis overlap was the most common combination (n = 35, 50.7%), followed by COPD-asthma overlap (n = 25, 36.2%) and asthma-bronchiectasis overlap (n = 11, 15.9%).

The composite endpoint and systemic comorbidities

Of the 1123 patients who had at least 1 CRD, 564 (50.2%) had severe or critical illness at hospital admission and 305 (27.2%) reached the composite endpoint within 30 days after hospitalization. Of the 69 patients with CRD overlap, 37 (53.6%) had severe or critical illness at hospital admission and 16 (23.2%) reached the composite endpoint within 30 days after hospitalization. Patients with CRD accounted for 4.5% (564 of 12,396) of patients with severe or critical illness at hospital admission and 5.5% (305 of 5559) of patients reaching the composite endpoint. Patients with CRD more frequently had systemic comorbidities (except for hepatitis B) and progressed to death compared with cases without CRD (all P < .01, Table II ).

Table II.

Clinical characteristics of patients with COVID-19 on admission and clinical outcomes

Clinical characteristics, treatments, and outcomes Severe cases
Reaching to composite endpoint
Survived
Died
No CRD (n = 11,832) Having CRD (n = 564) P value No CRD (n = 5254) Having CRD (n = 305) P value No CRD (n = 36,355) Having CRD (n = 1012) P value No CRD (n = 1942) Having CRD (n = 111) P value
Mean age (y) 60.3 70.7 <.001 62.6 71.6 <.001 54.6 67.6 <.001 70.5 75.6 <.001
Females, n (%) 5587 (47.2) 164 (29.1) <.001 2378 (45.3) 88 (28.9) <.001 18,664 (51.3) 342 (33.8) <.001 729 (37.5) 30 (27.0) .026
Respiratory symptoms, n (%)
 Fever at any time 9361 (79.1) 427 (75.7) .052 4097 (78.0) 234 (76.7) .607 24,642 (67.8) 698 (69.0) .424 1520 (78.3) 89 (80.2) .634
 Nasal congestion 1265 (10.7) 68 (12.1) .306 621 (11.8) 40 (13.1) .497 2782 (7.7) 86 (8.5) .319 211 (10.9) 11 (9.9) .753
 Headache 2403 (20.3) 99 (17.6) .111 924 (17.6) 56 (18.4) .730 5639 (15.5) 158 (15.6) .930 363 (18.7) 22 (19.8) .767
 Cough 9896 (83.6) 481 (85.3) .301 4105 (78.1) 244 (80.0) .442 27,138 (74.6) 818 (80.8) <.001 1460 (75.2) 86 (77.5) .585
 Sore throat 1223 (10.3) 61 (10.8) .715 466 (8.9) 28 (9.2) .853 3685 (10.1) 95 (9.4) .436 172 (8.9) 10 (9.0) .956
 Sputum production 9897 (83.6) 509 (90.2) <.001 4306 (82.0) 272 (89.2) .001 25,584 (70.4) 826 (81.6) <.001 1575 (81.1) 102 (91.9) .004
 Fatigue 6752 (57.1) 326 (57.8) .730 2681 (51.0) 166 (54.4) .248 17,482 (48.1) 530 (52.4) .007 973 (50.1) 65 (58.6) .083
 Shortness of breath 6248 (52.8) 384 (68.1) <.001 2856 (54.4) 205 (67.2) <.001 12,600 (34.7) 523 (51.7) <.001 1291 (66.5) 89 (80.2) .003
Other systemic comorbidities, n (%)
 Any 6048 (51.1) 409 (72.5) <.001 2971 (56.5) 238 (78.0) <.001 13,127 (36.1) 634 (62.6) <.001 1343 (69.2) 86 (77.5) .064
 Diabetes 2536 (21.4) 140 (24.8) .056 1355 (25.8) 86 (28.2) .351 4768 (13.1) 193 (19.1) <.001 566 (29.1) 24 (21.6) .088
 Hypertension 4278 (36.2) 278 (49.3) <.001 2186 (41.6) 169 (55.4) <.001 8913 (24.5) 419 (41.4) <.001 997 (51.3) 57 (51.4) .998
 Coronary heart disease 1159 (9.8) 126 (22.3) <.001 675 (12.8) 80 (26.2) <.001 1893 (5.2) 165 (16.3) <.001 338 (17.4) 39 (35.1) <.001
 Cerebrovascular diseases 874 (7.4) 95 (16.8) <.001 549 (10.4) 62 (20.3) <.001 1318 (3.6) 109 (10.8) <.001 287 (14.8) 26 (23.4) .014
 Hepatitis B 515 (4.4) 19 (3.4) .261 143 (2.7) 9 (3.0) .811 1407 (3.9) 46 (4.5) .273 46 (2.4) 4 (3.6) .412
 Malignancy 543 (4.6) 49 (8.7) <.001 275 (5.2) 25 (8.2) .026 1087 (3.0) 74 (7.3) <.001 121 (6.2) 7 (6.3) .974
 Chronic renal diseases 595 (5.0) 124 (22.0) <.001 368 (7.0) 80 (26.2) <.001 975 (2.7) 175 (17.3) <.001 204 (10.5) 28 (25.2) <.001
 Immunodeficiency 203 (1.7) 13 (2.3) .296 85 (1.6) 6 (2.0) .640 395 (1.1) 20 (2.0) .008 45 (2.3) 5 (4.5) .146
Complications during hospitalization, n (%)
 Septic shock 167 (1.4) 19 (3.4) <.001 160 (3.0) 19 (6.2) .002 36 (0.1) 9 (0.9) <.001 134 (6.9) 11 (9.9) .229
 Acute kidney injury 103 (0.9) 5 (0.9) .968 99 (1.9) 4 (1.3) .471 18 (0.0) 3 (0.3) .001 90 (4.6) 2 (1.8) .161
Treatments received during hospitalization, n (%)
 Intravenous antibiotics 7484 (63.3) 400 (70.9) <.001 3433 (65.3) 232 (76.1) <.001 18,700 (51.4) 592 (58.5) <.001 1317 (67.8) 81 (73.0) .257
 Antiviral therapy 7395 (62.5) 341 (60.5) .329 3187 (60.7) 183 (60.0) .819 21,819 (60.0) 555 (54.8) <.001 1121 (57.7) 63 (56.8) .841
 Inhaled corticosteroids 1334 (11.3) 152 (27.0) <.001 834 (15.9) 91 (29.8) <.001 2049 (5.6) 193 (19.1) <.001 249 (12.8) 19 (17.1) .191
 Systemic corticosteroids 4532 (38.3) 279 (49.5) <.001 2301 (43.8) 173 (56.7) <.001 7394 (20.3) 303 (29.9) <.001 1051 (54.1) 71 (64.0) .043
 Invasive ventilation 1400 (11.8) 113 (20.0) <.001 1400 (26.6) 113 (37.0) <.001 807 (2.2) 70 (6.9) <.001 593 (30.5) 43 (38.7) .069
 Noninvasive ventilation 1979 (16.7) 154 (27.3) <.001 1477 (28.1) 113 (37.0) <.001 1257 (3.5) 104 (10.3) <.001 873 (45.0) 54 (48.6) .447
 Extracorporeal membrane oxygenation 149 (1.3) 10 (1.8) .289 135 (2.6) 9 (3.0) .684 116 (0.3) 7 (0.7) .041 69 (3.6) 4 (3.6) .978
Median hospital stay (interquartile range) (d) 17 (11, 24) 17 (10, 27) .004 14 (8, 23) 16 (8, 28) <.001 15 (10, 22) 16 (11, 24) <.001 10 (5, 16) 10 (4, 18) .978
Intensive care unit admission, n (%) 3332 (28.2) 187 (33.2) .010 3332 (63.4) 187 (61.3) .458 2732 (7.5) 155 (15.3) <.001 600 (30.9) 32 (28.8) .646
Clinical outcomes, n (%)
 Discharge from hospital 10,096 (85.3) 461 (81.7) .019 3312 (63.0) 194 (63.6) .841
 Death 1736 (14.7) 103 (18.3) .019 1942 (37.0) 111 (36.4) .841

Bold values are statistical significance.

The denominators being lower than the total patient count suggested missing data.

Antiviral therapy consisted of lopinavir/ritonavir, remdesivir, chloroquine, hydrochloroquine, interferon-beta, arbidol, and favipinavir.

COVID-19, Coronavirus disease 2019; CRD, chronic respiratory disease.

Events that took place within 30 days after hospitalization.

Chronic respiratory diseases and the composite endpoint

Of the 12,396 patients with severe COVID-19, 564 patients had at least 1 CRD. Among the 5559 patients who reached the composite endpoint within day 30 after hospital admission, 305 patients had at least 1 CRD. Patients with CRD had an overall higher prevalence of other systemic comorbidities and more frequently required treatment for COVID-19 compared with those without CRD (Table II).

Within 30 days after hospitalization, patients with CRD had a markedly higher risk of reaching the composite endpoint compared with those without CRD (OR: 2.34, 95% CI: 2.05-2.68). Patients with COPD (OR: 3.22, 95% CI: 2.73-3.80) and asthma (OR: 1.66, 95% CI: 1.22-2.26), but not bronchiectasis, had a greater likelihood of reaching the composite endpoint compared with those without in the unadjusted analysis. Patients with COPD-asthma overlap (OR: 2.37, 95% CI: 0.99-5.68), but not COPD-bronchiectasis overlap (OR: 1.52, 95% CI: 0.66-3.48) nor asthma-bronchiectasis overlap (OR: 1.35, 95% CI: 0.29-6.25), were more likely to reach the composite endpoint compared with those without CRD overlap (Figure E1, available in this article's Online Repository at www.jaci-inpractice.org).

Figure E1.

Figure E1

Figure E1

CRD and the composite outcomes of COVID-19 in the unadjusted model. (A) The cumulative rate of reaching to the composite endpoints among patients with or without CRD based on the proportional hazards model. (B) The cumulative rate of reaching to the composite endpoints among patients with or without asthma, chronic obstructive pulmonary disease, or bronchiectasis based on the proportional hazards model. (C) The cumulative rate of reaching to the composite endpoints among patients with asthma-chronic obstructive pulmonary disease overlap, chronic obstructive pulmonary disease-bronchiectasis overlap, and asthma-bronchiectasis overlap based on the proportional hazards model. (D) Association between the severity of COVID-19, CRD, and clinical outcomes. The vertical colored bars represented the patient cohort, which was further categorized into different subgroups. The association between the different subgroups was presented with the gray bars, with greater width representing a greater magnitude of overlap. (E) Risk factors predicting the composite endpoints in patients with COVID-19. Shown are the numbers and percentages of patients with each of the category of disease who had reached the composite endpoint during the study and of patients who had not reached the composite endpoint. CI, Confidence interval; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRD, chronic respiratory disease; OR, odds ratio.

We have further adjusted the regression analysis with age, sex, and the presence of any other systemic comorbidities. Within 30 days after hospitalization, patients with CRD were associated with a significantly increased risk of reaching the composite endpoint compared with patients without CRD (OR: 1.49, 95% CI: 1.29-1.71). The strength of association between the CRD and the outcomes of COVID-19 remained significant albeit being slightly tempered compared with the unadjusted analysis. Table III shows the impact of the potential confounding factors on our analysis. Age, sex, and the presence of other systemic comorbidities were associated significantly with the risk of reaching the composite endpoint in patients with any CRD, COPD, and asthma (all P < .05).

Table III.

Adjusted regression analysis of the risks of death and reaching to the composite endpoint within 30 days after hospitalization

Composite endpoint Death
OR 95% CI P value OR 95% CI P value
Chronic respiratory diseases
 Presence of chronic respiratory diseases 1.49 1.29, 1.71 <.001 0.84 0.68, 1.04 .106
 Any other systemic comorbidity 1.75 1.64, 1.86 <.001 1.88 1.70, 2.08 <.001
 Female sex 1.30 1.23, 1.38 <.001 1.87 1.70, 2.05 <.001
 Age§ 1.03 1.02, 1.03 <.001 1.07 1.07, 1.08 <.001
COPD
 Presence of COPD 1.71 1.44, 2.03 <.001 1.01 0.80, 1.27 .956
 Any other systemic comorbidity 1.75 1.64, 1.86 <.001 1.88 1.69, 2.08 <.001
 Female sex 1.30 1.22, 1.38 <.001 1.85 1.68, 2.04 <.001
 Age§ 1.03 1.02, 1.03 <.001 1.07 1.07, 1.08 <.001
Asthma
 Presence of asthma 1.45 1.05, 1.98 .022 0.84 0.48, 1.48 .544
 Any other systemic comorbidity 1.76 1.65, 1.87 <.001 1.88 1.69, 2.08 <.001
 Female sex 1.32 1.24, 1.40 <.001 1.85 1.69, 2.04 <.001
 Age§ 1.03 1.02, 1.03 <.001 1.07 1.07, 1.08 <.001
Bronchiectasis
 Presence of bronchiectasis 0.91 0.67, 0.23 .534 0.38 0.21, 0.70 .002
 Any other systemic comorbidity 1.76 1.65, 1.87 <.001 1.88 1.70, 2.08 <.001
 Female sex 1.32 1.24, 1.40 <.001 1.86 1.69, 2.04 <.001
 Age§ 1.03 1.02, 1.03 <.001 1.07 1.07, 1.08 <.001

CI, Confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio.

Adjusted with the presence of any other systemic comorbidities, female sex, and age.

Adjusted with the presence of any chronic respiratory disease/COPD/asthma/bronchiectasis, female sex, and age.

Adjusted with any chronic respiratory disease/COPD/asthma/bronchiectasis, any other systemic comorbidities, and age.

§

Adjusted with any chronic respiratory disease/COPD/asthma/bronchiectasis, any other systemic comorbidities, and female sex.

Furthermore, patients with COPD (OR: 1.71, 95% CI: 1.44-2.03) and asthma (OR: 1.45, 95% CI: 1.05-1.98), but not bronchiectasis, were more likely to reach the composite endpoint compared with those without. However, the adjusted analysis did not seem to suggest that patients with CRD overlap had a greater risk of reaching the composite endpoint compared with those without CRD overlap (Figure 2 ).

Figure 2.

Figure 2

Figure 2

CRD and the composite outcomes of COVID-19 in the adjusted model. (A) The cumulative rate of reaching to the composite endpoints among patients with or without CRD based on the Cox proportional hazards model. (B) The cumulative rate of reaching to the composite endpoints among patients with or without asthma, chronic obstructive pulmonary disease, or bronchiectasis based on the Cox proportional hazards model. (C) The cumulative rate of reaching to the composite endpoints among patients with asthma-chronic obstructive pulmonary disease overlap, chronic obstructive pulmonary disease-bronchiectasis overlap, and asthma-bronchiectasis overlap based on the Cox proportional hazards model. (D) Association between the severity of COVID-19, CRD, and clinical outcomes. The vertical colored bars represented the patient cohort, which was further categorized into different subgroups. The association between the different subgroups was presented with the gray bars, with greater width representing a greater magnitude of overlap. E, Risk factors predicting the composite endpoints in patients with COVID-19. Shown are the numbers and percentages of patients with each of the category of disease who had reached to the composite endpoint during the study and of patients who had not reached to the composite endpoint. All models have been adjusted with female sex, age, and the presence of any other systemic comorbidities. CI, Confidence interval; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRD, chronic respiratory disease; OR, odds ratio.

Chronic respiratory diseases and death associated with COVID-19

Within day 30 after hospital admission, 2053 patients died and 37,367 patients survived. Among the survivors at day 30, 1012 (2.7%) had at least 1 CRD. Among the survivors, patients with CRD had a significantly greater symptom burden, had higher rates of other systemic comorbidities, and required more treatments compared with those without (all P < .05). However, among the nonsurvivors, few differences in demographic characteristics, symptom burden, and treatments were identified (Table II).

At day 30 after hospitalization, patients with CRD had an increased risk of dying from COVID-19 than those without CRD in the unadjusted analysis (OR: 2.05, 95% CI: 1.68-2.51). As shown in Table III, age, sex, and the presence of other systemic comorbidities were significantly associated with the risk of death in patients with any CRD, COPD, and asthma (all P < .05).

Moreover, patients with COPD (OR: 3.26, 95% CI: 2.61-4.08), but not asthma (OR: 1.11, 95% CI: 0.65-1.91) or bronchiectasis (OR: 0.66, 95% CI: 0.36-1.21), had a greater unadjusted risk of dying from COVID-19 (Figure E2, available in this article's Online Repository at www.jaci-inpractice.org).

Figure E2.

Figure E2

Figure E2

CRD and the risk of death COVID-19 in the unadjusted model. (A) The cumulative rate of mortality among patients with or without CRD based on the proportional hazards model. (B) The cumulative rate of mortality among patients with or without asthma, chronic obstructive pulmonary disease, or bronchiectasis based on the proportional hazards model. (C) The cumulative rate of mortality among patients with asthma-chronic obstructive pulmonary disease overlap, chronic obstructive pulmonary disease-bronchiectasis overlap, and asthma-bronchiectasis overlap based on the proportional hazards model. (D) Association between the severity of COVID-19, CRD, and mortality. The vertical colored bars represented the patient cohort, which was further categorized into different subgroups. The association between the different subgroups was presented with the gray bars, with greater width representing a greater magnitude of overlap. (E) Risk factors predicting mortality in patients with COVID-19. Shown are the numbers and percentages of patients with each of the category of disease who had reached the composite endpoint during the study and of patients who had not reached the composite endpoint. CI, Confidence interval; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRD, chronic respiratory disease; OR, odds ratio.

In the adjusted model, however, having CRD was not associated with a greater likelihood of dying from COVID-19 compared with those without CRD. Moreover, neither COPD nor asthma was significantly associated with the risk of death within 30 days after hospitalization. Bronchiectasis, however, seemed to confer a protective effect on the risk of death from COVID-19 in the adjusted analysis (OR: 0.38, 95% CI: 0.21-0.70). Finally, CRD overlap did not confer a higher risk of mortality within 30 days after hospitalization when taking into account the age, sex, and the presence of other systemic comorbidities (Figure 3 ).

Figure 3.

Figure 3

Figure 3

CRD and the risk of death COVID-19 in the adjusted model. (A) The cumulative rate of mortality among patients with or without CRD based on the Cox proportional hazards model. (B) The cumulative rate of mortality among patients with or without asthma, chronic obstructive pulmonary disease, or bronchiectasis based on the Cox proportional hazards model. (C) The cumulative rate of mortality among patients with asthma-chronic obstructive pulmonary disease overlap, chronic obstructive pulmonary disease-bronchiectasis overlap, and asthma-bronchiectasis overlap based on the Cox proportional hazards model. (D) Association between the severity of COVID-19, CRD, and mortality. The vertical colored bars represented the patient cohort, which was further categorized into different subgroups. The association between the different subgroups was presented with the gray bars, with greater width representing a greater magnitude of overlap. (E) Risk factors predicting mortality in patients with COVID-19. Shown are the numbers and percentages of patients with each of the category of disease who had reached to the composite endpoint during the study and of patients who had not reached to the composite endpoint. All models have been adjusted with female sex, age, and the presence of any other systemic comorbidities. CI, Confidence interval; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRD, chronic respiratory disease; OR, odds ratio.

Chronic respiratory diseases and intensive care unit admission and invasive ventilation associated with COVID-19

Two other important metrics, the admission to the intensive care unit and the need to receive invasive mechanical ventilation within 30 days after hospitalization, have also been further evaluated. The baseline characteristics of patients when stratified by the status of intensive care unit admission and invasive mechanical ventilation are shown in Table E1, Table E2 (available in this article's Online Repository at www.jaci-inpractice.org), respectively.

The risk of being admitted to the intensive care unit was higher in patients with CRD compared with those without CRD in both the unadjusted (Figure E3, available in this article's Online Repository at www.jaci-inpractice.org) and adjusted analysis (Figure E4, available in this article's Online Repository at www.jaci-inpractice.org). Although in the unadjusted analysis patients with CRD had an increased risk of needing invasive mechanical ventilation compared with those without CRD (Figure E5, available in this article's Online Repository at www.jaci-inpractice.org), this association no longer held after adjustment for age, sex, and other systemic comorbidities (Figure E6, available in this article's Online Repository at www.jaci-inpractice.org).

Figure E3.

Figure E3

Figure E3

CRD and the risk of intensive care unit admission in the unadjusted model. (A) The cumulative rate of admission to the intensive care unit among patients with or without CRD based on the proportional hazards model. (B) The cumulative rate of admission to the intensive care unit among patients with or without asthma, chronic obstructive pulmonary disease, or bronchiectasis based on the proportional hazards model. (C) The cumulative rate of admission to the intensive care unit among patients with asthma-chronic obstructive pulmonary disease overlap, chronic obstructive pulmonary disease-bronchiectasis overlap, and asthma-bronchiectasis overlap based on the proportional hazards model. (D) Association between the severity of COVID-19, CRD, and admission to the intensive care unit. The vertical colored bars represented the patient cohort, which was further categorized into different subgroups. The association between the different subgroups was presented with the gray bars, with greater width representing a greater magnitude of overlap. (E) Risk factors predicting the risk of admission to the intensive care unit in patients with COVID-19. Shown are the numbers and percentages of patients with each of the category of disease who had been admitted to the intensive care unit during the study and of patients who had not been admitted to the intensive care unit. CAID, chronic airway inflammatory diseases, which was equivalent to chronic respiratory diseases; CI, confidence interval; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRD, chronic respiratory disease; OR, odds ratio.

Figure E4.

Figure E4

Figure E4

CRD and the risk of intensive care unit admission in the adjusted model. (A) The cumulative rate of admission to the intensive care unit among patients with or without CRD based on the proportional hazards model. (B) The cumulative rate of admission to the intensive care unit among patients with or without asthma, chronic obstructive pulmonary disease, or bronchiectasis based on the proportional hazards model. (C) The cumulative rate of admission to the intensive care unit among patients with asthma-chronic obstructive pulmonary disease overlap, chronic obstructive pulmonary disease-bronchiectasis overlap, and asthma-bronchiectasis overlap based on the proportional hazards model. (D) Association between the severity of COVID-19, CRD, and admission to the intensive care unit. The vertical colored bars represented the patient cohort, which was further categorized into different subgroups. The association between the different subgroups was presented with the gray bars, with greater width representing a greater magnitude of overlap. (E) Risk factors predicting the risk of admission to the intensive care unit in patients with COVID-19. Shown are the numbers and percentages of patients with each of the category of disease who had been admitted to the intensive care unit during the study and of patients who had not been admitted to the intensive care unit. CAID, chronic airway inflammatory diseases, which was equivalent to chronic respiratory diseases; CI, confidence interval; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRD, chronic respiratory disease; OR, odds ratio.

Figure E5.

Figure E5

Figure E5

CRD and the risk of needing invasive ventilation in the unadjusted model. (A) The cumulative rate of needing invasive mechanical ventilation among patients with or without CRD based on the proportional hazards model. (B) The cumulative rate of needing invasive mechanical ventilation among patients with or without asthma, chronic obstructive pulmonary disease, or bronchiectasis based on the proportional hazards model. (C) The cumulative rate of needing invasive mechanical ventilation among patients with asthma-chronic obstructive pulmonary disease overlap, chronic obstructive pulmonary disease-bronchiectasis overlap, and asthma-bronchiectasis overlap based on the proportional hazards model. (D) Association between the severity of COVID-19, CRD, and the use of invasive mechanical ventilation. The vertical colored bars represented the patient cohort, which was further categorized into different subgroups. The association between the different subgroups was presented with the gray bars, with greater width representing a greater magnitude of overlap. (E) Risk factors predicting the risk of needing invasive mechanical ventilation in patients with COVID-19. Shown are the numbers and percentages of patients with each of the category of disease who needed invasive mechanical ventilation during the study and of patients who did not need invasive mechanical ventilation. CAID, chronic airway inflammatory diseases, which was equivalent to chronic respiratory diseases; CI, confidence interval; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRD, chronic respiratory disease; OR, odds ratio.

Figure E6.

Figure E6

Figure E6

CRD and the risk of needing invasive ventilation in the adjusted model. (A) The cumulative rate of needing invasive mechanical ventilation among patients with or without CRD based on the proportional hazards model. (B) The cumulative rate of needing invasive mechanical ventilation among patients with or without asthma, chronic obstructive pulmonary disease, or bronchiectasis based on the proportional hazards model. (C) The cumulative rate of needing invasive mechanical ventilation among patients with asthma-chronic obstructive pulmonary disease overlap, chronic obstructive pulmonary disease-bronchiectasis overlap, and asthma-bronchiectasis overlap based on the proportional hazards model. (D) Association between the severity of COVID-19, CRD, and the use of invasive mechanical ventilation. The vertical colored bars represented the patient cohort, which was further categorized into different subgroups. The association between the different subgroups was presented with the gray bars, with greater width representing a greater magnitude of overlap. (E) Risk factors predicting the risk of needing invasive mechanical ventilation in patients with COVID-19. Shown are the numbers and percentages of patients with each of the category of disease who needed invasive mechanical ventilation during the study and of patients who did not need invasive mechanical ventilation. CAID, chronic airway inflammatory diseases, which was equivalent to chronic respiratory diseases; CI, confidence interval; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRD, chronic respiratory disease; OR, odds ratio.

Discussion

By using the nationwide database that consisted of approximately 40,000 records, this study demonstrated a prevalence of 2.8% for any of the CRD among patients with COVID-19. The presence of any CRD correlated significantly with the risk of reaching the composite endpoint, but not death, of COVID-19 in both unadjusted and adjusted analysis. However, CRD were neither associated with the risk of reaching the composite endpoint nor death of COVID-19 after adjusting for the important confounding factors such as age, sex, and the presence of other systemic comorbidities.

Our findings pertaining to the mortality risk of COVID-19 were consistent with the observations by Lovinsky-Desir et al,14 who did not identify poorer clinical outcomes in patients with COVID-19 with asthma in a large cohort of patients without COPD. Moreover, García-Pachón et al15 did not identify an increased risk of being admitted to the hospital among asthmatic patients as compared with patients with COPD. By contrast, Zhu et al16 reported an elevated risk of developing severe COVID-19 among patients with asthma (mostly nonallergic) in a large cohort. COPD was associated with poorer outcomes in patients with COVID-19, which was consistent with our previous report despite the smaller sample size.5 A possible explanation for the difference in outcomes in asthma versus COPD was the difference in angiotensin-converting enzyme II expression (upregulated in COPD and downregulated in asthma).6 However, this point was not reaffirmed in another separate study that documented increased expression of angiotensin-converting enzyme II and transmembrane protease serines 2 in asthmatic patients,17 which has added complexity to the mechanisms. On the other hand, it has also been documented that inhaled corticosteroids attenuated angiotensin-converting enzyme II expression.18 Therefore, the more frequent use of inhaled corticosteroids in patients with asthma might help explain these findings. Nevertheless, the regular use of inhaled corticosteroids might have a negligible effect on the protection against COVID-19–related death among asthmatic patients and patients with COPD.19 Further mechanistic studies are warranted to decipher the link among CRD, use of inhaled corticosteroids, and the outcomes of COVID-19.

The findings related to the impact of comorbid bronchiectasis on the risk of death or reaching to the composite endpoint of COVID-19 were unexpected. No existing evidence pointing to the role of comorbid bronchiectasis on COVID-19 has been published. Although neutrophilic inflammation has been a dominant type of airway inflammatory response in both COPD and bronchiectasis, and patients with bronchiectasis might have elevated risks of developing viral-bacterial coinfection,20 bronchiectasis did not seem to confer adverse effects on the outcomes of COVID-19 in our study. We cannot conclude whether neutrophilic inflammation would predispose to a poorer outcome in patients with COVID-19 with bronchiectasis because of the lack of data pertaining to the airway inflammatory cell count in our study. It would be helpful to have lung function data that are currently lacking in our database.

Patients with CRD overlap did not seem to have poorer outcomes compared with those with individual CRD. However, the small number of patients with CRD overlap might have limited the statistical power to reach to a definitive conclusion. Hence, any conclusion on the impact of CRD overlap on the risk of reaching to the composite endpoint or death from COVID-19 might be premature. To this end, no further adjusted analysis was performed in our study and these exploratory findings should be interpreted with caution.

Age, sex, and the presence of other systemic comorbidities have also been associated with the clinical outcomes of COVID-19, which was consistent with the findings reported previously.5 , 7 , 9 Considering that these factors might have confounded our analysis, we have performed the regression analysis that mutually adjusted for these variables in our study. The models have reaffirmed the significant association of these variables with the clinical outcomes of COVID-19. Importantly, the strength of association for the risk of reaching the composite endpoint remained statistically significant after adjustment for these variables. Moreover, despite the lack of association between the risk of death and the CRD (except for bronchiectasis that might be a chance finding), each of these variables was significantly associated with the risk of death from COVID-19 in the multivariate regression model.

To our knowledge, this is the first nationwide study that explored the strength of association between CRD and their overlap and the clinical outcomes of COVID-19. A main strength of the study was the application of data analysis based on a nationwide database with a large sample size. Findings pertaining to bronchiectasis alone or in combination with asthma or COPD have not been reported previously. Our findings may have clinical implications to the triage and management of patients with COVID-19 who had underlying CRD.

However, our study has the major limitation of being a retrospective cohort study with other potential unmeasured confounding factors, despite the inclusion of age, sex, and the presence of other systemic comorbidities in the regression model. In conjunction with our earlier report1 and another study that specifically focused on the critically ill patients with COVID-19,11 the proportion of patients with CRD was relatively low compared with that in several other studies, probably due to the bias of self-report and a lack of documentation of CRD as the past history in the clinical charts, on which the extraction of medical records would depend in many regions of mainland China. In fact, an incomplete documentation of the comorbid diseases has been a notable challenge that constrains the acquisition of important medical history from the clinical charts in our real-world practice. Although we believe that the development of a nationwide electronic medical chart system would help alleviate the under-reporting of CRD, our findings were comparable with another separate study from mainland China.6 Because of the implementation of stringent nosocomial infection control measures, no lung function tests were performed provided that convalescence has not yet been achieved. The previous lung function records could not be traced because the current EMR was not linked to other existing databases. Several other important metrics reflecting the disease severity (ie, previous hospitalizations, medication prescription) also suffered from the incompleteness of documentation within the EMR. Therefore, we were unable to assess the association between the severity of CRD and the outcomes of COVID-19. The strength of association differed between the analysis on the composite endpoint and death, probably because of the limited number of death events as of data cutoff. Mechanistic investigations are needed to further decipher the association between CRD (especially COPD) and COVID-19. Furthermore, because of a high rate of incompleteness of information pertaining to the smoking status, we cannot comment whether the smoking status could have impacted on the study outcomes.

Conclusion

Our study has provided the evidence that CRD were significantly associated with the poor clinical outcomes of COVID-19 even after adjusting for the age, sex, and other systemic comorbidities. There was no additive effect of CRD overlap on the clinical outcomes of COVID-19 compared with the individual CRD, possibly because of the limited sample size for these subgroup analyses. Further exploration of the association between the severity of CRD and the outcomes of COVID-19 as well as the mechanistic underpinnings of these observations is needed.

Acknowledgments

We appreciate the approval and support from the National Health Commission for the utilization of the national database of COVID-19. We are grateful to Professor Yu-tong Lu, Yue-dong Yang, and Zhi-guang Chen of the National Supercomputer Center in Guangzhou (Tianhe-2 Supercomputer) for the support on data collection and storage. We thank Drs Yan-zhen Wang, Zhi-ye Zhou, and Er-song Shang of the China Standard Medical Information Research Center for their work on the data collection and data analysis.

WJG, WHL, JXH, HBW, and NSZ contributed to concept and design. YS, LXG, and HBW acquired, analyzed, or interpreted the data. WJG, WHL, and JXH drafted the manuscript. WJG, WHL, JXH, and HBW critically revised the manuscript for important intellectual content. YS and LXG performed statistical analysis. JXH, HBW, and NSZ provided administrative, technical, or material support. JXH, HBW, and NSZ contributed to supervision. JXH and HBW are the guarantors of the study. They had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Footnotes

This study is supported by National Health Commission (NSZ) and the National Natural Science Foundation of China (No.: U1611261) (HBW). Guangzhou Institute for Respiratory Health Open Project (funded by China Evergrande Group) Project No. 2020GIRHHMS09 and 2020GIRHHMS19 (WJG). The sponsors had no role in the data acquisition, analysis, and interpretation and writing of the report.

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Online Repository

Table E1.

Clinical characteristics of patients with COVID-19 on admission and clinical outcomes when stratified based on the status of intensive care unit admission

Clinical characteristics, treatments, and outcomes Not admitted to the ICU
Admitted to the ICU
No lower airway diseases (n = 34,965) Having lower airway diseases (n = 936) P value No lower airway diseases (n = 3332) Having lower airway diseases (n = 187) P value
Age (y) 55.0 68.2 <.001 59.5 69.5 <.001
Females, n (%) 17,798 (50.9) 313 (33.4) <.001 1595 (47.9) 59 (31.6) <.001
Respiratory symptoms, n (%)
 Fever at any time 23,558 (67.4) 647 (69.1) .260 2604 (78.2) 140 (74.9) .292
 Nasal congestion 2605 (7.5) 66 (7.1) .646 388 (11.6) 31 (16.6) .043
 Headache 5446 (15.6) 149 (15.9) .775 556 (16.7) 31 (16.6) .969
 Cough 25,960 (74.2) 755 (80.7) <.001 2638 (79.2) 149 (79.7) .868
 Sore throat 3608 (10.3) 89 (9.5) .421 249 (7.5) 16 (8.6) .585
 Sputum production 24,383 (69.7) 763 (81.5) <.001 2776 (83.3) 165 (88.2) .077
 Fatigue 16,764 (47.9) 494 (52.8) .004 1691 (50.8) 101 (54.0) .385
 Shortness of breath 12,235 (35.0) 497 (53.1) <.001 1656 (49.7) 115 (61.5) .002
Coexisting disorders, n (%)
 Any 12,718 (36.4) 574 (61.3) <.001 1752 (52.6) 146 (78.1) <.001
 Diabetes 4500 (12.9) 158 (16.9) <.001 834 (25.0) 59 (31.6) .046
 Hypertension 8609 (24.6) 371 (39.6) <.001 1301 (39.0) 105 (56.1) <.001
 Coronary heart disease 1874 (5.4) 159 (17.0) <.001 357 (10.7) 45 (24.1) <.001
 Cerebrovascular diseases 1316 (3.8) 93 (9.9) <.001 289 (8.7) 42 (22.5) <.001
 Hepatitis B 1365 (3.9) 43 (4.6) .283 88 (2.6) 7 (3.7) .365
 Malignancy 1076 (3.1) 63 (6.7) <.001 132 (4.0) 18 (9.6) <.001
 Chronic renal diseases 979 (2.8) 153 (16.3) <.001 200 (6.0) 50 (26.7) <.001
 Immunodeficiency 398 (1.1) 25 (2.7) <.001 42 (1.3) 0 (0.0) .122
Complications during hospitalization, n (%)
 Septic shock 80 (0.2) 7 (0.7) .001 90 (2.7) 13 (7.0) <.001
 Acute kidney injury 52 (0.1) 2 (0.2) .613 56 (1.7) 3 (1.6) .937
Treatments received during hospitalization, n (%)
 Intravenous antibiotics 17,843 (51.0) 529 (56.5) <.001 2174 (65.2) 144 (77.0) <.001
 Antiviral therapy 20,888 (59.7) 497 (53.1) <.001 2052 (61.6) 121 (64.7) .393
 Inhaled corticosteroids 1608 (4.6) 142 (15.2) <.001 690 (20.7) 70 (37.4) <.001
 Systemic corticosteroids 7098 (20.3) 277 (29.6) <.001 1347 (40.4) 97 (51.9) .002
 Invasive ventilation 839 (2.4) 62 (6.6) <.001 561 (16.8) 51 (27.3) <.001
 Noninvasive ventilation 1366 (3.9) 95 (10.1) <.001 764 (22.9) 63 (33.7) <.001
 Extracorporeal membrane oxygenation 105 (0.3) 7 (0.7) .015 80 (2.4) 4 (2.1) .819
Median hospital stay (interquartile range) (d) 15 (10, 21) 15 (9, 22) .000 16 (9, 25) 19 (11, 32) <.001
Clinical outcomes, n (%)
 Discharge from hospital 33,623 (96.2) 857 (91.6) <.001 2732 (82.0) 155 (82.9) .756
 Death 1342 (3.8) 79 (8.4) <.001 600 (18.0) 32 (17.1) .756

COVID-19, Coronavirus disease 2019; ICU, intensive care unit.

Outcomes that took place within 30 days after hospitalization.

Table E2.

Clinical characteristics of patients with COVID-19 on admission and clinical outcomes when stratified based on the need to receive invasive mechanical ventilation during hospitalization

Clinical characteristics, treatments, and outcomes Nonventilated cases
Ventilated cases
No lower airway diseases (n = 36,897) Having lower airway diseases (n = 1010) P value No lower airway diseases (n = 1400) Having lower airway diseases (n = 113) P value
Age (y) 55.0 68.0 <.001 64.9 72.4 <.001
Females, n (%) 18,818 (51.0) 350 (34.7) <.001 575 (41.1) 22 (19.5) <.001
Respiratory symptoms, n (%)
 Fever at any time 25,003 (67.8) 696 (68.9) .442 1159 (82.8) 91 (80.5) .543
 Nasal congestion 2840 (7.7) 79 (7.8) .883 153 (10.9) 18 (15.9) .106
 Headache 5701 (15.5) 154 (15.2) .860 301 (21.5) 26 (23.0) .708
 Cough 27,414 (74.3) 805 (79.7) <.001 1184 (84.6) 99 (87.6) .387
 Sore throat 3720 (10.1) 96 (9.5) .548 137 (9.8) 9 (8.0) .528
 Sputum production 25,854 (70.1) 818 (81.0) <.001 1305 (93.2) 110 (97.3) .086
 Fatigue 17,646 (47.8) 530 (52.5) .004 809 (57.8) 65 (57.5) .956
 Shortness of breath 12,914 (35.0) 522 (51.7) <.001 977 (69.8) 90 (79.6) .027
Coexisting disorders, n (%)
 Any 13,579 (36.8) 635 (62.9) <.001 891 (63.6) 85 (75.2) .013
 Diabetes 4922 (13.3) 189 (18.7) <.001 412 (29.4) 28 (24.8) .295
 Hypertension 9250 (25.1) 416 (41.2) <.001 660 (47.1) 60 (53.1) .223
 Coronary heart disease 2012 (5.5) 176 (17.4) <.001 219 (15.6) 28 (24.8) .011
 Cerebrovascular diseases 1418 (3.8) 119 (11.8) <.001 187 (13.4) 16 (14.2) .810
 Hepatitis B 1412 (3.8) 47 (4.7) .178 41 (2.9) 3 (2.7) .868
 Malignancy 1125 (3.0) 72 (7.1) <.001 83 (5.9) 9 (8.0) .384
 Chronic renal diseases 1105 (3.0) 174 (17.2) <.001 74 (5.3) 29 (25.7) <.001
 Immunodeficiency 415 (1.1) 23 (2.3) <.001 25 (1.8) 2 (1.8) .990
Complications during hospitalization, n (%)
 Septic shock 71 (0.2) 3 (0.3) .457 99 (7.1) 17 (15.0) .002
 Acute kidney injury 50 (0.1) 2 (0.2) .596 58 (4.1) 3 (2.7) .439
Treatments received during hospitalization, n (%)
 Intravenous antibiotics 18,861 (51.1) 566 (56.0) .002 1156 (82.6) 107 (94.7) <.001
 Antiviral therapy 21,839 (59.2) 528 (52.3) <.001 1101 (78.6) 90 (79.6) .802
 Inhaled corticosteroids 1942 (5.3) 167 (16.5) <.001 356 (25.4) 45 (39.8) <.001
 Systemic corticosteroids 7495 (20.3) 284 (28.1) <.001 950 (67.9) 90 (79.6) .009
 Noninvasive ventilation 1441 (3.9) 85 (8.4) <.001 689 (49.2) 73 (64.6) .002
 Extracorporeal membrane oxygenation 73 (0.2) 2 (0.2) .999 112 (8.0) 9 (8.0) .989
Median hospital stay (interquartile range) (d) 15 (10, 21) 16 (10, 23) <.001 17 (10, 25) 16 (9, 31) .989
Intensive care unit admission, n (%) 2771 (7.5) 136 (13.5) <.001 561 (40.1) 51 (45.1) .292
Clinical outcomes, n (%)
 Discharge from hospital 35,548 (96.3) 942 (93.3) .000 807 (57.6) 70 (61.9) .373
 Death 1349 (3.7) 68 (6.7) <.001 593 (42.4) 43 (38.1) .373

COVID-19, Coronavirus disease 2019.

Outcomes that took place within 30 days after hospitalization.

References

  • 1.World Health Organizaion Weekly operational update on COVID-19—13 November 2020. https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---13-november-2020 Available from:
  • 2.Gandhi R.T., Lynch J.B., Del Rio C. Mild or moderate Covid-19. N Engl J Med. 2020;383:1757–1766. doi: 10.1056/NEJMcp2009249. [DOI] [PubMed] [Google Scholar]
  • 3.Berlin D.A., Gulick R.M., Martinez F.J. Severe Covid-19. N Engl J Med. 2020;383:2451–2460. doi: 10.1056/NEJMcp2009575. [DOI] [PubMed] [Google Scholar]
  • 4.Liang W., Yao J., Chen A., Lv Q., Zanin M., Liu J. Early triage of critically ill COVID-19 patients using deep learning. Nat Commun. 2020;11:3543. doi: 10.1038/s41467-020-17280-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Guan W.J., Liang W.H., Zhao Y., Liang H.R., Chen Z.S., Li Y.M. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55:200054. doi: 10.1183/13993003.00547-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Song J., Zeng M., Wang H., Qin C., Hou H.Y., Sun Z.Y. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy. 2021;76:483–496. doi: 10.1111/all.14517. [DOI] [PubMed] [Google Scholar]
  • 7.Christensen D.M., Strange J.E., Gislason G., Torp-Pedersen C., Gerds T., Fosbøl E. Charlson Comorbidity Index score and risk of severe outcome and death in Danish COVID-19 patients. J Gen Intern Med. 2020;35:2801–2803. doi: 10.1007/s11606-020-05991-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Wang B., Li R., Lu Z., Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020;12:6049–6057. doi: 10.18632/aging.103000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Clark A., Jit M., Warren-Gash C., Guthrie B., Wang H.H.X., MercerSW Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8:e1003–e1017. doi: 10.1016/S2214-109X(20)30264-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Liu S., Cao Y., Du T., Zhi Y. Prevalence of comorbid asthma and related outcomes in COVID-19: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2021;9:693–701. doi: 10.1016/j.jaip.2020.11.054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Avdeev S., Moiseev S., Brovko M., Yavorovskiy A., Umbetova K., Akulkina L. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy. 2020;75:2703–2704. doi: 10.1111/all.14420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Wang L., Foer D., Bates D.W., Boyce J.A., Zhou L. Risk factors for hospitalization, intensive care and mortality among patients with asthma and COVID-19. J Allergy Clin Immunol. 2020;146:808–812. doi: 10.1016/j.jaci.2020.07.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.National Health Commission The diagnosis and treatment protocol for COVID-19 (Trial Version 5) http://www.nhc.gov.cn/xcs/zhengcwj/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml Available from:
  • 14.Lovinsky-Desir S., Deshpande D.R., De A., Murray L., Stingone J.A., Chan A. Asthma among hospitalized patients with COVID-19 and related outcomes. J Allergy Clin Immunol. 2020;146:1027–1034.e4. doi: 10.1016/j.jaci.2020.07.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.García-Pachón E., Zamora-Molina L., Soler-Sempere M.J., Baeza-Martínez C., Grau-Delgado J., Padilla-Navas I. Asthma and COPD in hospitalized COVID-19 patients. Arch Bronconeumol. 2020;56:604–606. doi: 10.1016/j.arbres.2020.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zhu Z., Hasegawa K., Ma B., Fujiogi M., Camargo C.A., Jr., Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol. 2020;146:327–329.e4. doi: 10.1016/j.jaci.2020.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Radzikowska U., Ding M., Tan G., Zhakparov D., Peng Y., Wawrzyiak P. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75:2829–2845. doi: 10.1111/all.14429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Finney L.J., Glanville N., Farne H., Aniscenko J., Fenwick P., Kemp S.V. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J Allergy Clin Immunol. 2021;147:510–519.e5. doi: 10.1016/j.jaci.2020.09.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Schultze A., Walker A.J., MacKenna B., Morton C.E., Bhaskaran K., Brown J.P. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8:1106–1120. doi: 10.1016/S2213-2600(20)30415-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Chen C.L., Huang Y., Yuan J.J., Li H.M., Han X.R., Martinez-Garcia M.A. The roles of bacteria and viruses in bronchiectasis exacerbation: a prospective study. Arch Bronconeumol. 2020;56:621–629. doi: 10.1016/j.arbr.2019.12.014. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Allergy and Clinical Immunology. in Practice are provided here courtesy of Elsevier

RESOURCES